Design and in vitro evaluation of a novel controlled onset extended-release delivery system of metoprolol tartrate

Jaber Emami, Mohammad-Reza Kazemali


Blood pressure rises rapidly upon awakening and maybe responsible, in part, for the increased incidence of myocardial infarction and stroke during the morning hours. The aim of the present study was, therefore, to develop a novel chronotherapeutic formulation of metoprolol tartrate (MT) for night time dosing providing maximum effect in the morning hours. Core tablets contained MT, sodium chloride, lactos, Avicel® and starch. Powders were mixed, sieved and directly compressed in to tablets using a single punch tablet machine. Core tablets were then coated with 5 or 10% hydroxypropylmethylcellulose as swelling layer and subsequently outer membrane with the mixture of various ratios of Eudragit® RS to RL at different coating levels 5, 10, 15% as semi-permeable water insoluble outer coat by conventional pan-spray method. The best formulation with regard to release behavior was chosen and subjected to further release studies in various rotational speed and pHs. Both lag time and release rate were dependent on the coating levels and the osmotic pressure of dissolution medium. A linear relationship between lag time and outer coating levels was observed. The lag time was prolonged with an increase in the coating levels. Both diffusion and osmotic pumping effect were involved in drug release from the device. Significant increases in drug release behavior was not observed using dissolution medium with various pH and different agitation rates. It was found that the release rate was independent of pH, rotational speed and gastric motility and may not be altered due to changes of pH and peristaltic movement along the GI tract. 

Full Text:



Fan TY, Wei SL, Yan WW, Chen DB, Li J. An investigation of pulsatile release tablets with ethylcellulose and Eudragit L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. J Controll Rel. 2001;77:245-251.

Stevens HNE. Chronopharmaceutical drug delivery in: Redfern P. Chronotherapeutics. London: Pharmaceutical Press; 2003. p. 283-307.

Youan BC. Chronopharmaceutics: gimmick or clinically relevant approach to drug delivery? J Control Release. 2004;98:337-353.

Smolensy MH, Peppas NA. Chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59:828-851.

Smolensy MH, Peppas NA. Preface, chronobiology, drug delivery, and chronotherapeutics. Adv Drug Deliv Rev. 2007;59:823-824.

Portaluppi F and Lemmer B. Chronobiology and chronotherapy of ischemic heart disease. Adv Drug Deliv Rev. 2007;59:952-965.

Haus E. Chronobiology of hemostasis and inferences for the chronotherapy of coagulation disorders and thrombosis prevention. Adv Drug Deliv Rev. 2007;59:966-984.

Behrens S, Ehlers C, Brüggemann T, Ziss W, Dissmann R, Galecka M, et al. Modification of the circadian pattern of ventricular tachyarrhythmia by beta-blocker therapy, Clin Cardiol. 1997; 20: 253–257.

Elliott WJ. Circadian variation in the timing of stroke onset. A metaanalysis. Stroke. 1998;29: 992–996.

Smolensky MH, Haus E. Circadian rhythms and clinical medicine with applications to hypertension. American J Hypertension. 2001;14:2805-2905.

Hermida RC, Ayala DE, Portaluppi F. Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. Adv Drug Deliv Rev. 2007;59:904-922.

Hermida RC, Ayala DE, Calvo C, Portaluppi F, Smolensky MH. Chronotherapy of hypertension: Administration-time-dependent effects of treatment on the circadian pattern of blood pressure. Adv Drug Deliv Rev. 2007;59:923-929.

Ravishankar H, Patil P, Samel A, Petereit HU, Lizio R, Iyer-Chavan J. Modulated release metoprolol succinate formulation based on ionic interactions: In vivo proof of concept. J Control Release. 2006;111:65–72.

Ayer AD, Theeuwes F, Wong PS. Pulsed drug delivery of doxylamine, US patent 4842867, 1989.

Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and or site-specific drug delivery. J Control Release. 2001;73:103-110.

Kroegel I, Bodmeeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res. 1998;15:474-481.

Ross AC, Macrae RJ, Walther M, Stevens HNE. Chronopharmaceutical drug delivery from a pulsatile capsule device based on programmable erosion. J Pharm Pharmacol. 2000;52:903-909.

Gupta SK, Atkinson L, Theeuwes F, Wong P, Gilbert PJ, Longstreth J. Pharmacokinetics of verapamil from an osmotic system with delayed onset. Eur J Pharm Biopharm. 1996;42:74-81.

Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev Ind Pharm. 2000;26:695-708.

Verma RK, Krishna DM, Garg S. Formulation aspects in the development of osmotically controlled oral drug delivery systems. J Control Release. 2002;79:7-27.

Sweetman SC. Martindale, the complete drug reference. London: The Pharmaceutical Press. 34th ed. Vol 1; 2005 p. 956-958.

Dadarwall SC, Madan S, Agrawal S. Formulation and evaluation of delayed-onset extended-release tablets of metoprolol tartrate using hydrophilic-swellable polymers. Acta Pharm. 2012;62:105–114.

Lin HL, Lin SY, Lin YK, Hoa H, Lo YW. Sheu MT. Release characteristics and in vitro–in vivo correlation of pulsatile pattern for a pulsatile drug delivery system activated by membrane rupture via osmotic pressure and swelling. Eur J Pharm Biopharm. 2008;70:289–301.

Jagdale1 SC, Chede SM, Gulwady R, Kuchekar BS, Lokhande PD, Shah TP, et al. Pulsatile multiparticulate drug delivery system for metoprolol succinate. Arch Pharm Res. 2011;34:369-376.

Costa P, Manuel J, Lobo S. Modeling and comparison of dissolution profiles. Eur J Pharm Sci. 2001;13:123–133.

Fan Ty, Wei SL, Yan WW, Chen DB, Li J. An investigation of pulsatile release tablets with ethylcellulose and Eudragit®L as film coating materials and cross-linked polyvinylpyrrolidone in the core tablets. J Control Release. 2001;77:245-251.

Smith DHG, Neutel JM, Weber MA. A new chronotherapeutic oral drug absorption system for verapamil optimizes blood pressure control in the morning. Am J Hypertens. 2001;14:14-19.

Zhang Y, Zhang Z, Wu F. A novel pulsed release system based on swelling and osmotic pumping mechanism. J Control Release. 2003;89:47-55.


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Creative Commons LicenseThis work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.